About Dicot Pharma

Dicot Pharma is a Uppsala-based pharmaceutical company collaborating with leading partners and renowned experts worldwide to develop the next generation of erectile dysfunction treatments. The goal is for the drug candidate LIB-01 to provide better treatment for erectile dysfunction and premature ejaculation compared to existing drugs.

Our clinical studies with LIB-01 focus on erectile dysfunction, and we are currently in Phase 2. Phase 1 demonstrated an excellent safety profile, along with a clear efficacy signal.

New research findings indicate that the substance may also influence factors related to metabolic diseases. A preclinical study is now underway in parallel with the development of the potency drug candidate.

An intensive IP-strategy has resulted in seven patent families and granted patents extending until 2042.

Dicot Pharma’s business model involves evaluating financial and industrial partnerships during the clinical development phase to bring LIB-01 to commercialization.